RFC3 serves as a novel prognostic biomarker and target for head and neck squamous cell carcinoma

• Published in: Clinical oral investigations 2023-11, Vol.27 (11), p.6961-6969
• Main Authors: AVS, Keerthana Reddy, Pandi, Chandra, Kannan, Balachander, Pandi, Anitha, Jayaseelan, Vijayashree Priyadharsini, Arumugam, Paramasivam
• Format: Article
• Language: English
• Subjects: Antigens; Biomarkers; Cancer; Carcinoma, Squamous Cell - pathology; Cell cycle; Cell division; Dentistry; DNA damage; Esophagus; Gene expression; Genomes; Head & neck cancer; Head and neck carcinoma; Head and Neck Neoplasms; Humans; Medical prognosis; Medicine; Metastasis; Mouth Neoplasms; Phase transitions; Prognosis; Proteins; Replication Protein C - metabolism; Squamous cell carcinoma; Squamous Cell Carcinoma of Head and Neck
• ISSN: 1436-3771; 1432-6981; 1436-3771
• DOI: 10.1007/s00784-023-05316-4

Objective Head and neck squamous cell carcinoma (HNSCC) is a prevalent cancer that originates from the squamous cells. The role of the replication factor C subunit 3 (RFC3) in HNSCC progression remains elusive. The aim of this study was to uncover RFC3 significance in HNSCC. Methods The Cancer Genome Atlas (TCGA-HNSCC) dataset was initially used to assess RFC3 expression and its association with HNSCC clinical features. Subsequently, quantitative reverse transcription PCR (RT-qPCR) confirmed RFC3 mRNA expression in oral squamous cell carcinoma (OSCC), a primary HNSCC type. Survival rates were evaluated using the Kaplan–Meier plot, while the Tumor Immune Estimation Resource (TIMER) database probed RFC3-immune cell interaction. Additionally, in silico tools were used to examine the RFC3 protein network and engagement in HNSCC pathways. Results RFC3 expression is significantly upregulated in HNSCC, including OSCC. Upregulated RFC3 expression was significantly correlated with the clinicopathological features of HNSCC, including tumor stage, grade, metastasis, and patient survival. RFC3 is also associated with immune cell infiltration. Functional analysis has highlighted its involvement in DNA replication, mismatch repair, and cell cycle pathways. Interestingly, RFC3 high expression is linked to well-known oncogenic signaling pathways, such as MYC/MYCN, HIPPO, and mTOR. Conclusions In conclusion, RFC3 can be considered a novel prognostic biomarker for HNSCC, and further studies on its functional mechanisms may help to use RFC3 as a therapeutic target for HNSCC. Clinical relevance The clinical relevance of this study lies in identifying RFC3 as a novel biomarker and prognostic indicator for HNSCC, offering insights that could impact future clinical approaches.